OncoMatch/Clinical Trials/NCT06125652
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Is NCT06125652 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies anti Tim-3/CD123 CAR-T cell therapy for acute myeloid leukemia refractory.
Treatment: anti Tim-3/CD123 CAR-T cell therapy — To evaluate the safety and efficacy of anti Tim3/CD123 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: autologous stem cell transplant
Exception: allowed if >3 months before enrollment
Auto-SCT within the 3 months before enrollment
Lab requirements
Blood counts
hemoglobin ≥60g/l
Kidney function
serum creatinine ≤1.5×uln, or ccr≥60 ml/min
Liver function
ast ≤3×uln; alt ≤3×uln; total bilirubin ≤1.5×uln
Cardiac function
lvef≥45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06125652 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous stem cell transplant disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages